Task: Please answer the following question about the molecule with SMILES CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO.
Request: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Completion: Phase 3 Clinical Trials
Task: Please answer the following question about the molecule with {SMILES__description} {SMILES#}.
{#Description|Question|Request!}: {quest#}
{#Result|Answer|Completion!}: {answ#}
CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO
CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.